Summary A major problem in the chemotherapy of colorectal cancers is their resistance to most cytotoxic drugs which may be due to insufficient cellular transport. Drugs conjugated to monoclonal antibodies recognising tumour antigens may overcome these difficulties by providing access of active agents to the tumour cells. The anti-tumour monoclonal antibody shown to localise in patients with colorectal cancer, 791T/36, has been investigated as a potential targeting antibody.
Colorectal carcinoma is one of the most common solid tumours in humans and is relatively resistant to all forms of currently available chemotherapy. Several groups have shown that antitumour antibodies can localise in colorectal cancer (Mach et al., 1980; Chatal et al., 1982) and it has been proposed that they may be used to direct therapeutic drugs to tumour cells. Monoclonal antibody, 791T/36, raised against osteogenic sarcoma cells (Embleton et al., 1981) binds to colorectal cancer cell (Durrant et al., 1986a) and has been shown to localise in colorectal cancer (Farrands et al., 1982; Armitage et al., 1984) . Conjugates synthesized between this antibody and methotrexate or daunomycin have been shown to be selectively cytotoxic against an osteogenic sarcoma cell line (Garnett et al., 1983; Gallego et al., 1984) . Dividing cells have been isolated from primary colorectal tumours (Durrant et al., 1986b) and their response to free drug or 791T/36-drug conjugates studied to assess their potential therapeutic usefulness in this common cancer.
Materials and methods
Clinical specimens Collection of surgically resected specimens, disaggregation and in vitro isolation of dividing tumour cell lines has previously been described (Durrant et al., 1986b) .
Cell culture
The basal medium consisted of Dulbecco's minimal essential medium (DMEM) supplemented with insulin (Sigma, Poole, Dorset, UK) and pyruvate (Flow Labs., Irving, Fife Indirect immunofluorescence Cells were stained by indirect immunofluorescence as previously described (Durrant et al., 1984) and analysed on a FACS IV (Becton Dickinson, Sunnyvale, Ca., USA). Fluorescein fluorescence was excited at 488 nm and collected via a 1Onm band with band pass filter centred at 515 nm after adjustment for standard conditions using fluorochromelabelled latex beads. Fluorescence intensity, expressed as mean linear fluorescence (MLF), was calculated by multiplying the contents of each channel by its channel number and dividing by the total number of cells in the distribution (Roe et al., 1985) . Each cell line was also stained using normal mouse Ig, and the MLF in this control was subtracted from the values obtained with monoclonal antibody. The percentage of cells staining was also calculated.
791T/36 monoclonal antibody recognises a glycoprotein of mol. wt. 72,000 which is found in osteogenic sarcomas, colon carcinomas and prostate carcinoma (Embleton et al., 1981; Price et al., 1983 (Durrant et al., 1986b) (Embleton & Garnett, 1985) . Briefly N-hydroxysuccinamide ester of methotrexate was prepared by the method of Kulkarni et al. (1981) and reacted with 791T/36 antibody for 1 h. Unreacted ester and unwanted small molecular weight products were removed by gel filtration on Sephadex G-25 column. A conjugate, designated MDC31, had one molecule of 791T/36 antibody substituted with an average of 2.7 molecules of methotrexate and retained 75% of its binding activity (Robins et al., 1986 (Durrant et al., 1986b) . Table I shows the clinicopathology of these primary tumours and compares the binding of 791T/36 monoclonal antibody in primary tumours and their in vitro culture derived cell lines. All the cell lines expressed 791T-p72 antigen. Furthermore 100% of cells growing in early in vitro culture (passage 5) express the antigen even when the primary tumours from which they were isolated had only a small weakly positive population. 791T/36 monoclonal antibody bound to the cells with varying intensities ranging from MLFs 138-454. The level of antigen expression was relatively stable in the majority of cell lines (Table II) . However, expression in line C146 varied from MLF127-MLF430 with no obvious correlation with passage number or growth characteristics.
Sensitivity of colorectal cell lines to cytotoxic drugs All the cell lines were screened by [75Se]-selenomethione assays for their sensitivity to three cytotoxic drugs, 5-fluorouracil, methotrexate and daunomycin (Table III) . Seven of the 8 lines had similar sensitivities to 5-fluorouracil whereas one was ten times more sensitive (Table III) . The cell lines varied in their sensitivities to daunomycin, 225 and 280 were very sensitive whereas C146 and C168 were resistant to the cytotoxic effects of daunomycin.
There was an enormous difference in sensitivity to methotrexate. Three of the lines grew efficiently in 1 mg ml -of methotrexate whereas other lines were killed by doses as small as 7ngml-'. This resistance was also observed when C170, C146 and C168 cell lines were assayed by a 14 day clonogenic assay (data not shown).
Resistance to methotrexate was gradually and irreversibly lost during continuous culture (Figure 1) . Between passages 0-60 all cell lines were 103 times less sensitive to methotrexate but by passage 200 C146, C168 and C170 cells were 104-105 times more sensitive to the cytotoxic effects of methotrexate. However resistance to daunomycin and 5-fluorouracil remained stable (data not shown).
Sensitivity of colorectal cells to 791T/36-drug conjugates
The instability of the cell lines as regards methotrexate sensitivity was not anticipated but as soon as it was observed (passage 50) the cell lines were screened for the sensitivity to 791T/36 conjugated to methotrexate. The C170, C146, C168 cells at this passage were still 103 fold more reistant than the other cell lines and 103 fold more resistant than they eventually became on further in vitro culturing. Furthermore the loss of resistance was irreversible, as growing cells following exposure to mutagens, in methotrexate failed to reverse the trend (unpublished data). C146, C168, C170 cell lines were more sensitive to the conjugated methotrexate than to the free drug at passage 50-53 (Figure 2 ). However as they continued to lose their resistance to free drug their sensitivity to conjugate remained unaltered (Table IV) . Cell lines which were very sensitive to free drug at early passages were less sensitive to 791T/36-methotrexate (Table IV) . C170 cells were injected into nude mice at in vitro passage number 40 (Durrant et al., 1986b) . Following 10 in vivo transplantations cells were reintroduced to in vitro culture and immediately assayed for methotrexate and 791T/36 methotrexate sensitivity. These cells had identical sensitivities to cells maintained in vitro culture for 50 passages and were Figure  3 ). Only two lines (C168 and C170) were screened with the daunomycin-791T/36 conjugate as it was in limited supply. Both lines had similar sensitivities to free or conjugated daunomycin although one line, C168 was 10 times more resistant than C170 (Figure 4 ). Methotrexate (g ml-') (Durrant et al., 1986) and may therefore act as a transplasma membrane carrier of cytotoxic drugs Shen et al., 1986) . (Davis, 1982; Gilbert, 1982) . Only 25% of the cell lines used in this study were more sensitive to 5-fluorouracil than methotrexate or daunomycin. They also had similar sensitivities to 5-fluorouracil as other colorectal lines developed in other laboratories (Dexter et al., 1981; Kimball & Brittain, 1980 (Shen et al., 1986) . As one of the major causes of methotrexate resistance is defective drug transport (Curt et al., 1984) , monoclonal antibody methotrexate conjugates should be much more effective in therapy of either naturally or acquired drug resistant tumours.
C146
Two of the cell lines which were resistant to daunomycin were treated with a 791T/36-daunomycin conjugate. However, unlike their response to 791T/36-methotrexate, they were as resistant to 791T/36-daunomycin as to free drug. Increased active transport of daunomycin out of cells has resulted in resistance to this drug (Dano, 1973) . Whether free drug was taken up by diffusion, or conjugated drug internalised as a monoclonal antibody conjugate, enhanced extracellular transport would result in similar resistance to free drug or monoclonal antibody drug conjugate.
The methotrexate resistant cell lines became increasingly sensitive to this drug in in vitro culture. However, expression of 791T p72 antigen, sensitivities to 5-fluorouracil and daunomycin, and their ability to grow as xenografts in nude mice remained unaltered. Similarly if the cell lines were passaged as xenotransplants in nude mice they still lost their methotrexate resistant at a similar rate to cells in in vitro culture. It must therefore be assumed that the environment of the human colon favours the growth of methotrexate resistant tumours, whereas in vitro culture or xenotransplantation in the flanks of nude mice favours the growth of methotrexate sensitive tumour cells.
Monoclonal antibody drug conjugates may not only reduce toxic side effects of drugs on normal cells but offer an alternative intracellular transport mechanism for cytotoxic drugs.
